Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

NCT ID: NCT03185143

Last Updated: 2021-04-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-27
• Study Completion Date: 2018-05-07

Brief Summary

This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.

Detailed Description

The study consists of a screening visit, outpatient treatment of a moderate or severe migraine attack with a single dose of the study drug within 8 weeks, and End-of-Study Visit 2-7 days after dosing.

Conditions

Migraine With and Without Aura

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Naltrexone and Acetaminophen Combination

Group Type: EXPERIMENTAL

Naltrexone and Acetaminophen Combination

Intervention Type: DRUG

Treat a single Qualified Migraine attack.

Sumatriptan 100 mg

Group Type: ACTIVE_COMPARATOR

Sumatriptan 100 mg

Intervention Type: DRUG

One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.

Interventions

Naltrexone and Acetaminophen Combination

Treat a single Qualified Migraine attack.

Intervention Type: DRUG

Sumatriptan 100 mg

One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.

Intervention Type: DRUG

Placebo

One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female 18 to 65 years of age.

2. History of migraine with or without aura according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with first migraine prior to age 50.

3. Migraine-associated nausea with ≥half the migraine attacks.

4. 2 - 8 migraines per month in each of the previous 3 months.

5. The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written informed consent and authorize HIPAA.

6. The female patient who is premenopausal or postmenopausal less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit to using 2 methods of adequate and reliable contraception throughout the study and for 28 days after taking the last dose of the study drug (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). Male patients must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after the study.ice, hormonal contraception).

Exclusion Criteria

1. The patient in the opinion of the investigator may have medication-overuse headaches (as defined by ICHD - 3 beta criteria for medication-overuse headache) during the preceding 3 months.

2. The patient in the opinion of the investigator has chronic migraine (as defined by ICHD - 3 beta criteria for chronic migraine) during the preceding 3 months.

3. History of cluster headaches or neurologically complicated migraine (hemiplegic, basilar, retinal, ophthalmoplegic).

4. Initiation or change in medications with possible migraine prophylactic effects during 3 months before inclusion into the trial (E.g., calcium channel blockers, tricyclic antidepressants, beta-blockers, or Botox).

5. Use of opiates or barbiturates more than 3 days per month.

6. Any concurrent medical or psychiatric condition, this includes, but is not limited to chronic unstable debilitating diseases, significant renal or hepatic impairment.

7. The patient has a history within the previous 3 years of abuse of any drug, prescription, illicit, or alcohol.

8. The Female patient is pregnant or breast-feeding. The Male patient is not practicing 2 different methods of birth control with their partner during the study, and for 28 days after the investigational drug last dose or will not remain abstinent during the study, and for 28 days after the last dose.

9. The patient has known-hypersensitivity reaction to any of the components of the investigational drug.

10. Consumption of analgesic medication or muscle relaxants (including all benzodiazepines) for other conditions on a regular basis.

11. The patient has used emergency care treatment more than 3 times in the previous 6 months.

12. The patient has participated in another study with an investigational drug within 30 days prior to randomization and/or plan to participate during the study.

13. The patient has a history of congenital heart disease, cardiac arrhythmias, or cardiovascular disease, e.g., ischemic heart disease (e.g., stable angina pectoris, unstable angina, vasospastic angina, myocardial infarction or silent myocardial ischemia), cerebrovascular syndromes (e.g., strokes of any type or transient ischemic attacks), peripheral vascular disease, ischemic bowel disease, or Raynaud syndrome.

14. Uncontrolled hypertension (sitting >160 mmHg systolic pressure or >95mmHg diastolic pressure).

15. The patient, in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease.

16. History of epilepsy. Allergy to sulfonamides.

17. Consumption of monoamine oxidase inhibitor (MAOI) drug, tricyclic antidepressant, selective serotonin reuptake inhibitor (SSRI) or Serotonin Noradrenaline Reuptake Inhibitor (SNRI).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Allodynic Therapeutics, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Annette C. Toledano, M.D.

Role: PRINCIPAL_INVESTIGATOR

Allodynic Therapeutics, Inc

Locations

Annette C. Toledano, M.D.

North Miami, Florida, United States

Countries

United States

Other Identifiers

ANODYNE-2

Identifier Type: -

Identifier Source: org_study_id